Riskpilot← Back to searchSign inGet full accessNOVA-CURE AS
ASActiveOrg 915719139Torggata 1, 2317 HamarGeneral medical practice activities · NACE 8621Est. 20152 employees
Revenue 2024
NOK 2,3M
-35% vs 2023
EBITDA margin
38.7%
-17% vs 2023
Equity ratio
-4.3%
Financial strength
Net profit 2024
NOK 706K
-17% vs 2023
| Revenue | NOK 2,3M | -35% |
| EBITDA | NOK 905K | -17% |
| Net profit | NOK 706K | -17% |
| Total assets | NOK 999K | -42% |
| Equity | NOK -43K | -160% |
| Employees | 2 | — |
Legal name
NOVA-CURE AS
Org number
915719139
Legal form
Aksjeselskap
NACE code
8621 · General medical practice activities
Founded
29. juli 2015
Share capital
NOK 30 000
Employees
2 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Medisinsk behandling, kurs-, foredrags- og undervisningsvirksomhet, konsulentvirksomhet, utarbeidelse av spesialisterklæringer og sakkyndige oppdrag.
Address
Torggata 1, 2317 Hamar
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 2 636 | 2 984 | 3 424 | 3 572 | 2 339 |
| Staff expenses | −815 | −596 | −1 039 | −1 157 | −720 |
| EBITDA | 921 | 1 486 | 1 376 | 1 092 | 905 |
| Depreciation & amort. | −192 | −192 | −0 | −0 | −0 |
| EBIT | 728 | 1 294 | 1 376 | 1 092 | 905 |
| Net financials | 0 | 0 | 0 | 0 | −0 |
| Profit before tax | 729 | 1 294 | 1 376 | 1 092 | 905 |
| Tax | 170 | 310 | 271 | 242 | 199 |
| Net profit | 558 | 984 | 1 104 | 849 | 706 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 004 | 1 565 | 1 633 | 1 711 | 999 |
| Equity | 39 | 173 | 37 | 72 | −43 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 965 | 1 392 | 1 595 | 1 639 | 1 042 |
| Total debt | 965 | 1 392 | 1 595 | 1 639 | 1 042 |
EBITDA margin
38.7%
This company
15.8%
Market median
+145% vs market
20202024
Equity ratio
-4.3%
This company
38.2%
Market median
-111% vs market
20202024
Return on equity
70561500.0%
This company
18.4%
Market median
+383486313% vs market
20202024
Net profit margin
30.2%
This company
8.1%
Market median
+273% vs market
20202024
Asset turnover
2.34×
This company
1.12×
Market median
+109% vs market
20202024
Debt / equity
24.28×
This company
0.62×
Market median
-3816% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
AT Chief Executive Officer | Chief Executive Officer | 2026 |
SK Chief Executive Officer | Chief Executive Officer | 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Board of Directors | 2025 | |
| Former (2) | ||
| Chairman | 2021 – 2024 | |
| Board of Directors | 2015 – 2021 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2024 | |
| Company | 50% | 50% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Lars Wefring As
NOVA-CURE AS Board members of NOVA-CURE AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Abdisa Tamirat Adugna | Chief Executive Officer | 0 companies |
| Sigrid Kristine Sele Haugtomt | Chief Executive Officer | 0 companies |
| Lars Wefring | Chairman | 0 companies |
| Stefan Haugtomt Haug | Board of Directors | 0 companies |
| Inger Eline Wetten Tjønneland | Board of Directors | 0 companies |